Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.

Front Endocrinol (Lausanne) · 2022 · PMC9520252 · PMID 36187118

Europe PMC DOI

hedged sentences

0.1830

closest p · 3.7× alpha

0.1830

boldest claim

The sentences

did not reach statistical significanceP=0.183not close (p > 0.1)

The use of metformin was associated with a numerically longer m OS of 43 months (95% CI 32.498-53.502) than the use of other anti-diabetics of 35 months (95% CI 24.787-45.213), but the difference did not reach statistical significance(P=0.183), Figure 3A .

also in 111,027 other papers

showed a trendno p-value reported

Our results show that the 3-year survival rate of patients in BCLC stages A to C who were treated with metformin all showed a trend of improvement.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.